Plain-English translation of NCT07191483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing KYN-5356, a new medication designed to help improve thinking and memory problems that often occur with schizophrenia. About 150 adults will be randomly assigned to take either the new medication at different doses or a placebo (dummy pill) for 28 days. The research team will carefully measure whether the medication helps improve thinking skills and track any side effects.
Many people with schizophrenia struggle with memory, attention, and other thinking skills — even when their main symptoms are well-controlled by their current medications. This trial is designed to see if this new treatment can help address these thinking and memory problems, which could improve quality of life.
You likely qualify if…
You likely don't qualify if…
You would move into a clinic for about 32 days so researchers can closely monitor you. You'll take a daily tablet (either the new medication or a placebo) for 28 days, and the study team will run tests to measure your thinking skills, check your safety, and gather blood samples. After you leave the clinic on Day 29, you'll return for one final follow-up visit about 2 weeks later.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States